How to Identify and Manage High-Risk Smoldering Multiple Myeloma.

Biomarkers Early intervention High-risk smoldering multiple myeloma Prediction models Risk stratification

Journal

Current oncology reports

ISSN: 1534-6269

Titre abrégé: Curr Oncol Rep

Pays: United States

ID NLM: 100888967

Informations de publication

Date de publication:
23 Aug 2024

Historique:

accepted: 06 08 2024

medline: 23 8 2024

pubmed: 23 8 2024

entrez: 23 8 2024

Statut: aheadofprint

Résumé

It elucidates advancements in identifying and managing high-risk smoldering multiple myeloma (SMM), moving from observation strategies to intervention approaches. It highlights the significance of differentiating high-risk SMM from its less aggressive counterparts to prevent progression to multiple myeloma (MM). Recent developments have improved SMM risk-stratification, integrating clinical, molecular and biological markers to identify high-risk individuals accurately. The advent of dynamic risk models that incorporate disease evolution and the application of novel diagnostic technologies are enhancing the understanding of SMM. Clinical trials exploring low to high intensity interventions, have shown promise in delaying MM onset and improving patient prognosis. There is a significant change in high-risk SMM management, leaning towards early intervention and precision medicine. The focus now is on refining these approaches, exploring new treatments, and proving the sustained benefits of early interventions to ultimately improve SMM patient care and outcomes.

Identifiants

DOI: 10.1007/s11912-024-01596-5 PMID: 39177708

pubmed: 39177708

doi: 10.1007/s11912-024-01596-5

pii: 10.1007/s11912-024-01596-5

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9. https://doi.org/10.1056/NEJMoa054494 .

doi: 10.1056/NEJMoa054494 pubmed: 16571879

Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9(12):102. https://doi.org/10.1038/s41408-019-0263-z .

doi: 10.1038/s41408-019-0263-z pubmed: 31836698 pmcid: 6910906

Thorsteinsdottir S, Gislason GK, Aspelund T, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29(2):467–72. https://doi.org/10.1038/s41591-022-02183-6 .

doi: 10.1038/s41591-022-02183-6 pubmed: 36747117 pmcid: 11099842

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5 .

doi: 10.1016/S1470-2045(14)70442-5 pubmed: 25439696

Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–90. https://doi.org/10.1056/NEJMoa070389 .

doi: 10.1056/NEJMoa070389 pubmed: 17582068

Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9. https://doi.org/10.1056/NEJMoa01133202 .

doi: 10.1056/NEJMoa01133202 pubmed: 11856795

Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123(3):338–45. https://doi.org/10.1182/blood-2013-05-505487 .

doi: 10.1182/blood-2013-05-505487 pubmed: 24222331 pmcid: 3894492

van de Donk NW, Palumbo A, Johnsen HE, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984–96. https://doi.org/10.3324/haematol.2013.100552 .

doi: 10.3324/haematol.2013.100552 pubmed: 24658815 pmcid: 4040895

Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7. https://doi.org/10.1038/leu.2010.60 .

doi: 10.1038/leu.2010.60 pubmed: 20410922 pmcid: 7020664

Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–12. https://doi.org/10.1016/S1470-2045(19)30309-2 .

doi: 10.1016/S1470-2045(19)30309-2 pubmed: 31162104

Messiou C, Porta N, Sharma B, et al. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol Imaging Cancer. 2021;3(5):e210048. https://doi.org/10.1148/rycan.2021210048 .

doi: 10.1148/rycan.2021210048 pubmed: 34559006 pmcid: 8489453

Wennmann M, Goldschmidt H, Mosebach J, et al. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage. Br J Haematol. 2022;199(1):65–75. https://doi.org/10.1111/bjh.18232 .

doi: 10.1111/bjh.18232 pubmed: 35608264

Mellgard G, Gilligan M, Cliff ERS, et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere. 2024;8(3):e61. https://doi.org/10.1002/hem3.61 .

doi: 10.1002/hem3.61 pubmed: 38510991 pmcid: 10951870

Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92. https://doi.org/10.1182/blood-2007-05-088443 .

doi: 10.1182/blood-2007-05-088443 pubmed: 17576818

Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785–9. (Research Support, N.I.H., Extramural). https://doi.org/10.1182/blood-2007-08-108357 .

Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–5. https://doi.org/10.1038/leu.2012.237 .

doi: 10.1038/leu.2012.237 pubmed: 22902364

Perez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148(1):110–4. https://doi.org/10.1111/j.1365-2141.2009.07929.x .

doi: 10.1111/j.1365-2141.2009.07929.x pubmed: 19821821

Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–8. https://doi.org/10.3324/haematol.11080 .

doi: 10.3324/haematol.11080 pubmed: 18268286

Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631–6. https://doi.org/10.1046/j.1365-2141.2003.04654.x .

doi: 10.1046/j.1365-2141.2003.04654.x pubmed: 14616966

Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738–44. https://doi.org/10.1038/leu.2013.86 .

doi: 10.1038/leu.2013.86 pubmed: 23515097 pmcid: 3773463

Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(34):4325–32. https://doi.org/10.1200/JCO.2012.48.4923 .

doi: 10.1200/JCO.2012.48.4923

Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc. 2010;85(3):300. https://doi.org/10.4065/mcp.2009.0653 .

doi: 10.4065/mcp.2009.0653 pubmed: 20194156 pmcid: 2843123

Visram A, Rajkumar SV, Kapoor P, et al. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >/=100. Leukemia. 2022;36(5):1429–31. https://doi.org/10.1038/s41375-022-01529-w .

doi: 10.1038/s41375-022-01529-w pubmed: 35190659 pmcid: 9064933

Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. https://doi.org/10.1038/s41408-018-0077-4 .

doi: 10.1038/s41408-018-0077-4 pubmed: 29895887 pmcid: 5997745

Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. https://doi.org/10.1038/s41408-020-00366-3 .

doi: 10.1038/s41408-020-00366-3 pubmed: 33067414 pmcid: 7567803

Termini R, Zihala D, Terpos E, et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res : Off J Am Assoc Cancer Res. 2022;28(21):4771–81. https://doi.org/10.1158/1078-0432.CCR-22-1594 .

doi: 10.1158/1078-0432.CCR-22-1594

Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6(7):e454. https://doi.org/10.1038/bcj.2016.65 .

doi: 10.1038/bcj.2016.65 pubmed: 27471870 pmcid: 5030386

Fernandez de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia. 2018;32(6):1427–34. https://doi.org/10.1038/s41375-018-0013-4 .

doi: 10.1038/s41375-018-0013-4 pubmed: 29463830

Rodríguez-Lobato LG, de Daniel i Bisbe A, Tovar N, et al. Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma. ASH: Blood; 2022:4341–4342.

Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470–9. https://doi.org/10.1182/bloodadvances.2018016998 .

doi: 10.1182/bloodadvances.2018016998 pubmed: 29945937 pmcid: 6020804

Visram A, Rajkumar SV, Kapoor P, et al. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021;11(11):186. https://doi.org/10.1038/s41408-021-00569-2 .

doi: 10.1038/s41408-021-00569-2 pubmed: 34836942 pmcid: 8626440

Cowan A, Ferrari F, Freeman SS, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10(3):e203–12. https://doi.org/10.1016/S2352-3026(22)00386-6 .

doi: 10.1016/S2352-3026(22)00386-6 pubmed: 36858677 pmcid: 9991855

Burgos L, Tamariz-Amador LE, Puig N, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J Clin Oncol : Off J Am Soc Clin Oncol. 2023;41(16):3019–31. https://doi.org/10.1200/JCO.22.01916 .

doi: 10.1200/JCO.22.01916

Bustoros M, Sklavenitis-Pistofidis R, Park J, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol : Off J Am Soc Clin Oncol. 2020;38(21):2380–9. https://doi.org/10.1200/JCO.20.00437 .

doi: 10.1200/JCO.20.00437

Bustoros M, Anand S, Sklavenitis-Pistofidis R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13(1):3449. https://doi.org/10.1038/s41467-022-30694-w .

doi: 10.1038/s41467-022-30694-w pubmed: 35705541 pmcid: 9200804

Kazandjian D, Diamond B, Papadimitriou M, et al. Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma. Clin Cancer Res : Off J Am Assoc Cancer Res. 2024. https://doi.org/10.1158/1078-0432.CCR-24-0210 .

doi: 10.1158/1078-0432.CCR-24-0210

Dutta AK, Fink JL, Grady JP, et al. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33(2):457–68. https://doi.org/10.1038/s41375-018-0206-x .

doi: 10.1038/s41375-018-0206-x pubmed: 30046162

Boyle EM, Deshpande S, Tytarenko R, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021;12(1):293. https://doi.org/10.1038/s41467-020-20524-2 .

doi: 10.1038/s41467-020-20524-2 pubmed: 33436579 pmcid: 7804406

Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9(1):3363. https://doi.org/10.1038/s41467-018-05058-y .

doi: 10.1038/s41467-018-05058-y pubmed: 30135448 pmcid: 6105687

Boiarsky R, Haradhvala NJ, Alberge JB, et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun. 2022;13(1):7040. https://doi.org/10.1038/s41467-022-33944-z .

doi: 10.1038/s41467-022-33944-z pubmed: 36396631 pmcid: 9672303

Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493–506. https://doi.org/10.1038/s43018-020-0053-3 .

doi: 10.1038/s43018-020-0053-3 pubmed: 33409501 pmcid: 7785110

Botta C, Maia C, Garces JJ, et al. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Adv. 2022;6(2):690–703. https://doi.org/10.1182/bloodadvances.2021005198 .

doi: 10.1182/bloodadvances.2021005198 pubmed: 34587246 pmcid: 8791585

Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer cell 2022;40(11):1358–1373 e8. https://doi.org/10.1016/j.ccell.2022.10.017 .

Ojo AS, Akinyemi O, Araoye MO, Ali A. Early intervention with a curative intent through an intensive therapy versus immunologic disease control using a minimal intensity approach in the management of high-risk smoldering multiple myeloma: a systematic review of evidence from clinical trials. Clin Lymphoma Myeloma Leuk. 2023;23(1):e27–40. https://doi.org/10.1016/j.clml.2022.10.009 .

doi: 10.1016/j.clml.2022.10.009 pubmed: 36402701

Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–36. https://doi.org/10.1016/S1470-2045(16)30124-3 .

doi: 10.1016/S1470-2045(16)30124-3 pubmed: 27402145

Mateos MV, Hernandez MT, Salvador C, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. Eur J Cancer. 2022;174:243–50. https://doi.org/10.1016/j.ejca.2022.07.030 .

doi: 10.1016/j.ejca.2022.07.030 pubmed: 36067617

Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2020;38(11):1126–37. https://doi.org/10.1200/JCO.19.01740 .

doi: 10.1200/JCO.19.01740

Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34(7):1840–52. https://doi.org/10.1038/s41375-020-0718-z .

doi: 10.1038/s41375-020-0718-z pubmed: 32024950 pmcid: 7326703

Landgren O, Chari A, Cohen YC, et al. Efficacy and Safety of Daratumumab (DARA) Monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study. ASH: Blood; 2023:210.

Manasanch EE, Jagannath S, Lee HC, et al. A multicenter phase ii single arm trial of isatuximab in patients with high risk smoldering multiple Myeloma (HRSMM). ASH: Blood; 2019:3116.

Kumar SK, Alsina M, Laplant B, et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial. ASH: Blood; 2022:1830–1832.

Mateos MV, Martínez-López J, Rodríguez-Otero P, et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): Post-Hoc analysis of sustained undetectable measurable residual disease (MRD). ASH: Blood; 2022:292–294.

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. https://doi.org/10.1016/S0140-6736(21)00933-8 .

doi: 10.1016/S0140-6736(21)00933-8 pubmed: 34175021

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. https://doi.org/10.1056/NEJMoa2024850 .

doi: 10.1056/NEJMoa2024850 pubmed: 33626253

Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2203478 .

doi: 10.1056/NEJMoa2203478 pubmed: 36449420 pmcid: 10587778

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–44. https://doi.org/10.1056/NEJMoa2204591 .

doi: 10.1056/NEJMoa2204591 pubmed: 36507686

Nadeem O, Magidson S, Midha S, et al. Immuno-PRISM: A Randomized phase II Platform study of bispecific antibodies in high-risk smoldering myeloma. ASH: Blood; 2023;206. https://doi.org/10.1182/blood-2023-177954 .

Abdallah NH, Lakshman A, Kumar SK, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024;14(1):9. https://doi.org/10.1038/s41408-024-00980-5 .

doi: 10.1038/s41408-024-00980-5 pubmed: 38228628 pmcid: 10791688

Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11(5):94. https://doi.org/10.1038/s41408-021-00480-w .

doi: 10.1038/s41408-021-00480-w pubmed: 34001889 pmcid: 8128921

El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022;9(5):e340–9. https://doi.org/10.1016/S2352-3026(22)00069-2 .

doi: 10.1016/S2352-3026(22)00069-2 pubmed: 35344689 pmcid: 9067621

Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–75. https://doi.org/10.1182/blood-2014-09-568899 .

doi: 10.1182/blood-2014-09-568899 pubmed: 25838344 pmcid: 4432003

Musto P, Engelhardt M, Caers J, et al. 2021 European myeloma network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr Hyde Haematologica. 2021;106(11):2799–812. https://doi.org/10.3324/haematol.2021.278519 .

doi: 10.3324/haematol.2021.278519

Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia. 2014;28(9):1902–8. https://doi.org/10.1038/leu.2014.75 .

doi: 10.1038/leu.2014.75 pubmed: 24535407